Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Perrine Roux 1, 2, * Maria Sullivan 2 Julien Cohen 1 Lionel Fugon 1 Jermaine Jones 2 Suzanne Vosburg 2 Ziva Cooper 2 Jeanne Manubay 2 Shanthi Mogali 2 Sandra Comer 2
* Auteur correspondant
1 SESSTIM - U912 INSERM - AMU - IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
2 Division on Substance Abuse
Abstract : Few studies have examined abuse of prescription opioids among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. The current 7-week inpatient study assessed oral oxycodone self-administration by patients with chronic pain who had a history of opioid abuse. Participants (n=25) were transitioned from their preadmission prescribed opioid to Bup/Nx. All of the participants were tested under each of the sublingual Bup/Nx maintenance doses (2/0.5, 8/2 or 16/4 mg) in random order. During each maintenance period, participants could self-administer oxycodone orally (0, 10, 20, 40 or 60 mg prescription opioids) or receive money during laboratory sessions. Drug choice (percentage) was the primary dependent variable. Subjective ratings of clinical pain and withdrawal symptoms also were measured. Mann-Whitney tests compared percentage of drug choice for each active oxycodone dose to placebo. Logistic regression analyses identified correlates of oxycodone preference, defined as 60% or greater choice of oxycodone compared to money. Pain was significantly reduced while participants were maintained on Bup/Nx compared to preadmission ratings. No differences in percentage drug choice were observed between the active oxycodone doses and placebo under each Bup/Nx maintenance dose. However, factors associated with oxycodone preference were lower Bup/Nx maintenance dose, more withdrawal symptoms and more pain. These data suggest that Bup/Nx was effective in reducing pain and supplemental oxycodone use. Importantly, adequate management of pain and withdrawal symptoms by Bup/Nx may reduce oxycodone preference in this population.
Type de document :
Article dans une revue
PAIN, Elsevier, 2013, 154 (8), pp.1442-8. 〈10.1016/j.pain.2013.05.004〉
Liste complète des métadonnées

Littérature citée [39 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00903499
Contributeur : Perrine Roux <>
Soumis le : mardi 12 novembre 2013 - 12:14:54
Dernière modification le : mercredi 5 septembre 2018 - 15:56:02
Document(s) archivé(s) le : jeudi 13 février 2014 - 04:45:24

Fichiers

Rouxetal-final-revised.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

UNIV-AMU | IRD

Citation

Perrine Roux, Maria Sullivan, Julien Cohen, Lionel Fugon, Jermaine Jones, et al.. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.. PAIN, Elsevier, 2013, 154 (8), pp.1442-8. 〈10.1016/j.pain.2013.05.004〉. 〈inserm-00903499〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

386

Téléchargements de fichiers

427

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD